Whalesbook
UTI AMC Reports Q3 FY26 Financial Performance
UTI Asset Management Company (UTI AMC) announced its financial results for the third quarter of fiscal year 2026 (Q3 FY26), reporting a consolidated profit after tax (PAT) of ₹121 crore. This figure represents a year-on-year decrease from the ₹151 crore posted in the same quarter of the previous fiscal year, though it indicated a 7% sequential increase from the September quarter's ₹113 crore. The reported profitability was influenced by a one-time voluntary retirement scheme (VRS) charge, which affected results.
On a normalized basis, excluding exceptional items like the VRS charge, UTI AMC's consolidated PAT surged by 43% year-on-year to ₹216 crore. Total income from operations saw a robust increase, rising by 23% year-on-year to ₹518 crore for the quarter ending December 31, 2025. The company's total group Assets Under Management (AUM) reached ₹23.15 lakh crore, an 11.44% increase year-on-year. UTI Mutual Fund's quarterly average AUM (QAAUM) stood at ₹3,93,809 crore as of December 31, 2025, with equity assets comprising 70% of this total.
The company's market capitalization was approximately ₹13,626.68 crore as of Thursday's trading session. UTI AMC has historically maintained a debt-free status, demonstrating strong financial footing.
Industry Context and Analyst Sentiment
The broader asset management sector has seen market attention, with capital market firms experiencing a recent uptick following SEBI's finalization of the expense ratio framework, which proved less impactful than initially feared. Earlier in the week, however, proposed changes to mutual fund fee structures had led to some market volatility for AMC stocks. UTI AMC's focus on digital adoption, with a significant portion of sales originating from digital platforms, and expansion in B30 cities continue to be strategic drivers.
Following the Q3 results, equity analysts largely maintained a positive view on UTI AMC. Antique Stock Broking reiterated its 'Buy' rating, setting a revised target price of ₹1,225 from ₹1,530. The brokerage anticipates a 14% compound annual growth rate (CAGR) in mutual fund AUM and a 10% CAGR in profit after tax over FY25-FY28, while acknowledging ongoing market share challenges but viewing the stock as a value play. Motilal Oswal also reaffirmed its 'Buy' recommendation with a one-year target price of ₹1,400, highlighting the need to improve equity scheme performance for enhanced yield. Centrum Broking upgraded the stock to 'Buy' from 'Neutral', considering the recent ~23% stock correction as excessive and citing attractive valuations, while noting fund flow challenges as a key concern.
Market Reaction
Shares of UTI AMC saw an upward movement on Thursday, rising over 3% and outperforming the benchmark Nifty 50, which advanced 0.93% during the same period. The stock touched an intraday high of ₹1,066.7 per share, marking its most significant intraday gain since mid-December 2025. As of 09:55 AM, the stock was trading 2.3% higher at ₹1,058 apiece. This rise helped snap a two-day losing streak for the shares, which have seen a 6.2% decline year-to-date, contrasting with the Nifty 50's 3% advance. Trading volume was noted at 1.9 times the average 30-day volume. The P/E ratio for UTI AMC was approximately 20.08 as of January 22, 2026.